Amyotrophic Lateral Sclerosis (ALS)

ALS Research Briefs: News from 2012 AAN Conference

Among the reports given at the 2012 annual meeting of the American Academy of Neurology, being held April 21-28 in New Orleans, was information about research into amyotrophic lateral sclerosis (ALS).

Neuromuscular Disease Research Discussed at 2012 AAN Meeting

Top scientists and clinicians from around the world are discussing the latest research in neuroscience, and the care of individuals with nerve and muscle diseases, at the 2012 annual meeting of the American Academy of Neurology in New Orleans, April 21-28.

MDA 2012 Clinical Conference Report: ALS Best Practices

Several experts presented their views of best practices for care of people with ALS at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Best practices outlined in this article include:

MDA 2012 Conference Report: Best Practices

Several experts presented their views of "best practices" for care of people with neuromuscular disorders at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Many questions remain about optimal care in these disorders, but it's clear that attention to heart and respiratory function are of paramount importance.

This article looks at:

ALS Research Briefs: SOD1, Repeat Expansions

SOD1 causes toxicity in some familial and some sporadic ALS

In some people with bulbar-onset sporadic ALS, changes to the SOD1 protein cause the same toxicity as is generated by mutated SOD1 protein in the familial (inherited) form of the disease, a team of researchers has reported.

MDA 2012 Conference Report: Targeted Therapies

The progress of several experimental therapies currently in development for neuromuscular diseases was discussed at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.

Neuralstem Phase 1 Stem Cell Trial Shows Safety, Possible Efficacy

Neuralstem's spinal cord stem cells, and the surgical technique used to transplant them, proved to be safe and well-tolerated in a phase 1 clinical trial in 12 people with amyotrophic lateral sclerosis (ALS). Although the trial wasn't designed to show efficacy, one participant showed signs of clinical improvement.

ALS TDI Webinar: TDI 132 Project Overview

An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.

MDA 2012 Conference Report: Genetics and Immunology Update

More than 500 physicians, allied health care professionals and MDA staff attended the MDA's 2012 Clinical Conference in Las Vegas, March 4-7.

The program emphasized:

MDA and ALS TDI Extend Partnership Through 2012

MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments forALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).

Pages